
Proceedings of the WFH’s Third Global Forum on the Safety and Supply of Hemophilia Treatment Products
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia
Year: 2016
Language: English
This resource is also available in: Arabic French Russian Spanish Simplified Chinese
Author(s): World Federation of Hemophilia
Format: Document
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia

This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Farsi A description of

Also Available In: English, Spanish This is not an official WFH translation. This resource has been translated with permission by

Helps identify effective treatment strategies for hemophilia. Topics include delivery of treatment, on-demand treatment, prophylaxis, immune tolerance, and factor assays.

The Hemophilia Treatment Centre (HTC) Twinning program pairs emerging HTCs with established ones to help increase the levels of diagnosis

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia